Aumolertinib - Jiangsu Hansoh Pharmaceutical
Alternative Names: Almonertinib; AMEILE; Amerol; Aumolertinib mesylate - Jiangsu Hansoh Pharmaceutical; EQ-143; HS-10206; HS-10296; HS-10296 mesylateLatest Information Update: 28 Jul 2024
At a glance
- Originator Jiangsu Hansoh Pharmaceutical
- Developer EQRx; Henan Cancer Hospital; Jiangsu Hansoh Pharmaceutical
- Class Acrylamides; Amines; Antineoplastics; Cyclopropanes; Indoles; Pyrimidines; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Non-small cell lung cancer
- Phase I Solid tumours
- No development reported Meningeal carcinomatosis
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(In volunteers) in New Zealand (PO, Tablet)
- 31 May 2024 Efficacy and adverse events data from a phase-II clinical trials in Non-small cell lung cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 28 Apr 2024 No recent reports of development identified for clinical-Phase-Unknown development in Meningeal-carcinomatosis(First-line therapy, Newly diagnosed, Recurrent, Second-line therapy or greater) in China (PO, Tablet)